Reported 2025 year-end financial results, with a net loss of $11.6 million, an improvement from $16.3 million in 2024. Raised over $20 million in gross proceeds in 2025, resulting in $11.9 million in cash and cash equivalents as of December 31, 2025. Extended the company's cash runway into the second quarter of 2027. The IT-01 Study manuscript for INT230-6 in 64 refractory metastatic cancer patients was published in eBioMedicine, reporting a 75% disease control rate and median overall survival of 11.9 months. Preliminary observations from the INVINCIBLE-4 Study in triple negative breast cancer (TNBC) showed 71.4% pathological complete response (pCR) in patients receiving INT230-6 prior to standard of care (SOC) compared to 33% in the SOC alone arm. The INVINCIBLE-4 Study also observed 44% fewer grade 3 or higher adverse events in the INT230-6 + SOC cohort. Full approval was granted on March 26, 2026, to resume enrollment for the INVINCIBLE-4 Study. The INVINCIBLE-3 Study (Phase 3 for soft tissue sarcoma) paused new site activations and patient enrollments in March 2025 due to funding constraints, with 21 patients enrolled prior to the pause. Research and development expenses decreased to $6.8 million in 2025 from $10.5 million in 2024, primarily due to lower INVINCIBLE-3 Study costs and no new manufacturing batches of INT230-6. General and administrative expenses decreased to $5.2 million in 2025 from $6.1 million in 2024, driven by lower stock-based compensation and cost efficiencies.